## PODD: Insulet Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -5.0% below STRENGTH zone (4.0-10.0%); PEG 2.15 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($291.42)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 10, Bearish: 0)

**1. FDA OKs Algorithm Updates to Insulet’s Omnipod 5 Insulin Pump**
- Source: Medical Product Outsourcing | 20251204T151542 | Bullish | Relevance: 100%
- Insulet has received FDA 510(k) clearance for enhancements to its Omnipod 5 automated insulin delivery (AID) system. These updates to the Omnipod 5 algorithm include a lower 100 mg/dL Target Glucose option and a more seamless automated experience. The new features are expected to launch in the U.S. in the first half of 2026 for individuals aged 2 and older with type 1 diabetes and aged 18 and older with type 2 diabetes.

**2. Insulet Announces FDA 510(k) Clearance of Omnipod® 5 Algorithm Enhancements that Redefine Insulin Delivery and Simplify the Pod Experience**
- Source: BioSpace | 20251204T150448 | Bullish | Relevance: 100%
- Insulet Corporation has received FDA 510(k) clearance for significant enhancements to its Omnipod 5 Automated Insulin Delivery System. These updates include a new 100 mg/dL Target Glucose setting for more customization and improved glucose management, alongside an enhanced algorithm to keep users in Automated Mode longer. The improvements are expected to launch in the U.S. in the first half of 2026 for individuals aged 2 and older with type 1 diabetes and aged 18 and older with type 2 diabetes.

**3. Insulet wins FDA clearance for Omnipod 5 algorithm enhancements**
- Source: MassDevice | 20251204T124510 | Bullish | Relevance: 100%
- Insulet has received FDA 510(k) clearance for new enhancements to its Omnipod 5 system. These updates include a lower 100 mg/dL target glucose option and a more seamless automated experience for its tubeless, wearable automated insulin delivery patch pump. Omnipod 5 is the first FDA-cleared tubeless automated insulin delivery system, proactively correcting high glucose and protecting against lows.

**4. Insulet Announces FDA 510(k) Clearance of Omnipod® 5 Algorithm Enhancements that Redefine Insulin Delivery and Simplify the Pod Experience**
- Source: Yahoo Finance | 20251204T121020 | Bullish | Relevance: 100%
- Insulet Corporation has received FDA 510(k) clearance for significant enhancements to its Omnipod 5 Automated Insulin Delivery System. These updates include a new 100 mg/dL Target Glucose option, expanding customization, and an enhanced algorithm designed to keep users in Automated Mode with fewer interruptions, improving the overall user experience. The enhancements aim to provide more precise insulin delivery, supporting tighter glucose management and simplifying the daily lives of people with diabetes.

**5. Insulet Announces FDA 510(k) Clearance of Omnipod® 5 Algorithm Enhancements that Redefine Insulin Delivery and Simplify the Pod Experience**
- Source: Stock Titan | 20251204T120910 | Bullish | Relevance: 100%
- Insulet Corporation (NASDAQ: PODD) has received FDA 510(k) clearance for significant enhancements to its Omnipod 5 Automated Insulin Delivery System. These updates include a new 100 mg/dL Target Glucose option, offering greater customization and tighter glucose management, and an enhanced algorithm designed to keep users in Automated Mode with fewer interruptions. These advancements are expected to launch in the United States in the first half of 2026 for individuals aged 2 and older with type 1 diabetes and 18 and older with type 2 diabetes.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 13, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-24 | Canaccord Genui | $432 | $428 | +1% |
| 2025-11-21 | Truist Securiti | $412 | $390 | +6% |
| 2025-11-21 | RBC Capital | $380 | $370 | +3% |
| 2025-11-21 | BTIG | $380 | $370 | +3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-24 | Canaccord Genui | main | Buy |
| 2025-11-21 | Truist Securiti | main | Buy |
| 2025-11-21 | RBC Capital | main | Outperform |
| 2025-11-21 | BTIG | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 3 ($0.80M) |
| Sells | 1 ($0.54M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 55.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+1.0%)
- FMR, LLC: 10.8% (+0.8%)
- Blackrock Inc.: 9.4% (+2.8%)
- Capital Research Glo: 6.5% (-4.0%)
- State Street Corpora: 4.4% (+1.1%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.8% 5d) with bearish MACD, trend may be turning.
2. Premium valuation (P/E 51x, PEG 2.2x) vulnerable to multiple compression.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 13 raises (avg +5%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.15 elevated, pricing in significant growth expectations. Balance sheet: strong liquidity (2.9x). Revenue growth strong at 21% YoY. Analyst sentiment positive (13 raises, avg +5%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.3B |
| Beta | 1.38 |
| 52W Range | $230.05 - $354.88 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.15 |
| Forward P/E | 51.1 |
| Current P/E | 64.6 |
| YoY Growth | 26.4% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from -1.2% to -5.0% (-3.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 9.0pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.1%) - potential reversal signal. Underperforming sector by 3.5pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.05x) but short-term weakness (below SMA20). MACD histogram bearish (-2.46), momentum weakening. RSI neutral at 46. OFD pattern: +MLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.96% (CS: 8) | Weak |
| RSI_14 | 46.3 | Neutral |
| MACD Histogram | -2.46 | Bearish |
| vs SMA20 | 0.971x | Below |
| vs SMA50 | 0.986x | Below |
| vs SMA200 | 1.051x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $315.92
- **Stop Loss:** $291.42 (7.8% risk)
- **Target:** $340.42 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 20
- **Position Value:** $6,318.40
- **Portfolio %:** 6.32%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-19 (Est: $1.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.15 | $1.24 | +8.1% |
| 2025Q2 | $0.92 | $1.17 | +26.8% |
| 2025Q1 | $0.79 | $1.02 | +29.7% |
| 2024Q4 | $1.02 | $1.15 | +12.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*